61060 Federal Register / Vol. 71, No.
200 / Tuesday, October 17, 2006 / Notices
Bancorporation, Billings, Montana, and
thereby indirectly acquire Clarke
County State Bank, Osceola, Iowa,
Farmers & Merchants State Bank,
Iroquois, South Dakota, and Farmers
State Bank, Stickney, South Dakota.
Board of Governors of the Federal Reserve
System, October 12, 2006.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. E6–17194 Filed 10–16–06; 8:45 am]
BILLING CODE 6210–01–S
FEDERAL RESERVE SYSTEM
Notice of Proposals to Engage in
Permissible Nonbanking Activities or
to Acquire Companies that are
Engaged in Permissible Nonbanking
Activities
The companies listed in this notice
have given notice under section 4 of the
Bank Holding Company Act (12 U.S.C.
1843) (BHC Act) and Regulation Y (12
CFR part 225) to engage de novo, or to
acquire or control voting securities or
assets of a company, including the
companies listed below, that engages
either directly or through a subsidiary or
other company, in a nonbanking activity
that is listed in § 225.28 of Regulation Y
(12 CFR 225.28) or that the Board has
determined by Order to be closely
related to banking and permissible for
bank holding companies. Unless
otherwise noted, these activities will be
conducted throughout the United States.
Each notice is available for inspection
at the Federal Reserve Bank indicated.
The notice also will be available for
inspection at the offices of the Board of
Governors. Interested persons may
express their views in writing on the
question whether the proposal complies
with the standards of section 4 of the
BHC Act. Additional information on all
bank holding companies may be
obtained from the National Information
Center Web site at http://www.ffiec.gov/
nic/.
Unless otherwise noted, comments
regarding the applications must be
received at the Reserve Bank indicated
or the offices of the Board of Governors
not later than November 1, 2006.
A. Federal Reserve Bank of Chicago
(Patrick M. Wilder, Assistant Vice
President) 230 South LaSalle Street,
Chicago, Illinois 60690-1414:
1. First Internet Bancorp,
Indianapolis, Indiana; to acquire
Landmark Financial Corporation,
sroberts on PROD1PC70 with NOTICES
Indianapolis, Indiana, and thereby
indirectly acquire Landmark Savings
Bank, Indianapolis, Indiana, and
Landmark Mortgage Company,
Indianapolis, Indiana, and thereby
VerDate Aug<31>2005 06:27 Oct 17, 2006 Jkt 211001
engage in the operation of a savings
association and lending activities,
pursuant to sections 225.28(b)(1) and
(b)(4)(ii) of Regulation Y.
Board of Governors of the Federal Reserve
System, October 12, 2006.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. E6–17195 Filed 10–16–06; 8:45 am]
BILLING CODE 6210–01–S
FEDERAL RESERVE SYSTEM
Sunshine Act Meeting
AGENCY HOLDING MEETING: Board of
Governors of the Federal Reserve
System.
TIME AND DATE: 12:00 p.m., Monday,
October 23, 2006.
PLACE: Marriner S. Eccles Federal
Reserve Board Building, 20th and C
Streets, NW., Washington, DC 20551.
STATUS: Closed.
MATTERS TO BE CONSIDERED: 1. Personnel
actions (appointments, promotions,
assignments, reassignments, and salary
actions) involving individual Federal
Reserve System employees.
2. Any items carried forward from a
previously announced meeting.
FOR FURTHER INFORMATION CONTACT:
Michelle Smith, Director, or Dave
Skidmore, Assistant to the Board, Office
of Board Members at 202–452–2955.
SUPPLEMENTARY INFORMATION: You may
call 202–452–3206 beginning at
approximately 5 p.m. two business days
before the meeting for a recorded
announcement of bank and bank
holding company applications
scheduled for the meeting; or you may
contact the Board’s Web site at http://
www.federalreserve.gov for an electronic
announcement that not only lists
applications, but also indicates
procedural and other information about
the meeting.
Board of Governors of the Federal Reserve
System, October 13, 2006.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. 06–8757 Filed 10–13–06; 2:47 pm]
BILLING CODE 6210–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration on Aging
Agency Information Collection
Activities; Extension of Collection;
Comment Request; Title III and VII
State Program Report
AGENCY: Administration on Aging, HHS.
PO 00000 Frm 00047 Fmt 4703 Sfmt 4703 E:\FR\FM\17OCN1.SGM
ACTION: Notice.
SUMMARY: The Administration on Aging
(AoA) is announcing an opportunity for
public comment on the extension of
collection of certain information by the
agency. Under the Paperwork Reduction
Act of 1995 (the PRA), Federal agencies
are required to publish notice in the
Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information, and
to allow 60 days of public comment in
response to the notice. This notice
solicits comments on the information
collection requirements relating to Title
III and VII State Program Report.
DATES: Submit written or electronic
comments on the collection of
information by December 18, 2006.
ADDRESSES: Submit electronic
comments on the collection of
information to:
saadia.greenberg@aoa.hhs.gov. Submit
written comments on the collection of
information to Administration on Aging,
Office of Evaluation, Washington, DC
20201 Attention: SPR Comments.
FOR FURTHER INFORMATION CONTACT:
Saadia Greenberg at 202–357–3554 or e-
mail: saadia.greenberg@aoa.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency request
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, AoA is publishing notice
of the extension of collection of
information set forth in this document.
With respect to the following collection
of information, AoA invites comments
on: (1) Whether the collection of
information is necessary for the proper
performance of AoA’s functions,
including whether the information will
have practical utility; (2) the accuracy of
AoA’s estimate of the burden of the
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
17OCN1
 Federal Register / Vol. 71, No. 200 / Tuesday, October 17, 2006 / Notices
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques
when appropriate, and other forms of
information technology.
The Older Americans Act (OAA)
requires annual program performance
reports from States. In compliance with
this OAA provision, AoA developed a
new State Program Report (SPR) in 1996
as part of its National Aging Program
Information System (NAPIS). The SPR
collects information about how State
Agencies on Aging expend their OAA
funds as well as funding from other
sources for OAA authorized supportive
services. The SPR also collects
information on the demographic and
functional status of the recipients. This
collection was revised in November
2004 (OMB Approval Number 0985–
0008). The proposed data collection
continuation format remains unchanged
from the November 2004 document. It
may be found on the AoA Web site at
http://www.aoa.gov/prof/agingnet/
NAPIS/docs/SPR-Modified-Form-
11.08.04.pdf. AoA estimates the burden
of this collection of information as
follows: 2,606 hours.
Dated: October 12, 2006.
Josefina G. Carbonell,
Assistant Secretary for Aging.
[FR Doc. E6–17251 Filed 10–16–06; 8:45 am]
BILLING CODE 4154–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2006N–0018]
Anne L. Butkovitz; Debarment Order
AGENCY: Food and Drug Administration,
HHS.
ACTION: Notice.
SUMMARY: The Food and Drug
Administration (FDA) is issuing an
order under the Federal Food, Drug, and
Cosmetic Act (the act) permanently
debarring Ms. Anne L. Butkovitz from
providing services in any capacity to a
person that has an approved or pending
drug product application including, but
not limited to, a biologics license
application. FDA bases this order on a
finding that Ms. Butkovitz was
convicted of a felony under Federal law
sroberts on PROD1PC70 with NOTICES
for conduct relating to the development
or approval, including the process for
development or approval, of a drug
product under the act. After being given
notice of the proposed permanent
VerDate Aug<31>2005 06:27 Oct 17, 2006 Jkt 211001
debarment and her opportunity to
request a hearing within the timeframe
prescribed by regulation, Ms. Butkovitz
failed to request a hearing. Ms.
Butkovitz’s failure to request a hearing
constitutes a waiver of her right to a
hearing concerning this action.
DATES: This order is effective October
17, 2006.
ADDRESSES: Submit applications for
termination of debarment to the
Division of Dockets Management (HFA–
305), Food and Drug Administration,
5630 Fishers Lane, rm. 1061, Rockville,
MD 20852.
FOR FURTHER INFORMATION CONTACT:
Brenda R. Friend, Center for Biologics
Evaluation and Research (HFM–17),
Food and Drug Administration, 1401
Rockville Pike, Rockville, MD 20852–
1448, 301–827–6210.
SUPPLEMENTARY INFORMATION:
I. Background
On June 7, 2005, the U.S. District
Court for the District of Massachusetts
accepted Ms. Anne L. Butkovitz’s plea
of guilty to one count of making a false
statement, a Federal felony offense
under 18 U.S.C. 1001. This offense was
committed while Ms. Butkovitz was the
clinical study coordinator at a safety site
for a clinical trial.
As a result of this conviction, FDA
served Ms. Butkovitz by certified mail
on March 7, 2006, a notice proposing to
permanently debar Ms. Butkovitz from
providing services in any capacity to a
person that has an approved or pending
drug product application including, but
not limited to, a biologics license
application. The proposal also offered
Ms. Butkovitz an opportunity for a
hearing on the proposal. The proposal
was based on a finding, under section
306(a)(2)(A) and (c)(2)(A)(ii) of the act
(21 U.S.C. 335a(a)(2)(A) and
(c)(2)(A)(ii)), that Ms. Butkovitz was
convicted of a felony under Federal law
for conduct relating to the development
or approval of a drug product, including
the process for development or
approval, of a drug product. Ms.
Butkovitz was provided 30 days to file
objections and request a hearing. Ms.
Butkovitz did not request a hearing. Ms.
Butkovitz’s failure to request a hearing
constitutes a waiver of her opportunity
for a hearing and a waiver of any
contentions concerning her debarment
(21 CFR 12.22(b)(1)).
II. Findings and Order
Therefore, the Director of the Center
for Biologics Evaluation and Research,
under section 306(a)(2)(A) of the act,
and under authority delegated to the
Director (FDA Staff Manual Guide
PO 00000 Frm 00048 Fmt 4703 Sfmt 4703 E:\FR\FM\17OCN1.SGM
61061
1410.35), finds that Ms. Butkovitz has
been convicted of a felony under
Federal law for conduct relating to the
development or approval, including the
process for development or approval, of
a drug product.
As a result of the foregoing finding,
Ms. Butkovitz is permanently debarred
from providing services in any capacity
to a person with an approved or
pending drug product application
(section 306(c)(1)(B) of the act). A drug
product means a drug, including a
biological product, subject to regulation
under sections 505, 512, or 802 of the
act (21 U.S.C. 355, 360b, or 382), or
under section 351 of the Public Health
Service Act (42 U.S.C. 262). Any person
with an approved or pending drug
product application including, but not
limited to, a biologics license
application, who knowingly employs or
retains as a consultant or contractor, or
otherwise uses the services of Ms.
Butkovitz, in any capacity, during Ms.
Butkovitz’s permanent debarment, will
be subject to civil money penalties
(section 307(a)(6) of the act (21 U.S.C.
335b(a)(6))). If Ms. Butkovitz, during her
permanent debarment, provides services
in any capacity to a person with an
approved or pending drug product
application including, but not limited
to, a biologics license application, Ms.
Butkovitz will be subject to civil money
penalties (section 307(a)(7) of the act).
In addition, FDA will not accept or
review any abbreviated new drug
applications submitted by or with the
assistance of Ms. Butkovitz during Ms.
Butkovitz’s permanent debarment
(section 306(c)(1)(B) of the act).
Any application by Ms. Butkovitz for
termination of debarment under section
306(d)(4) of the act should be identified
with Docket Number 2006N–0018 and
sent to the Division of Dockets
Management (see ADDRESSES). All such
submissions are to be filed in four
copies (21 CFR 10.20(a)). The public
availability of information in these
submissions is governed by 21 CFR
10.20(j). Publicly available submissions
may be seen in the Division of Dockets
Management between 9 a.m. and 4 p.m.,
Monday through Friday (21 CFR
10.20(j)(1)).
Dated: September 25, 2006.
Jesse Goodman,
Director, Center for Biologics Evaluation and
Research.
[FR Doc. E6–17178 Filed 10–16–06; 8:45 am]
BILLING CODE 4160–01–S
17OCN1